1. Asmundson GJ, Taylor S, Smits JA. Panic disorder and agoraphobia: an overview and commentary on DSM-5 changes. Depress Anxiety 2014;31:480-486.
3. Perna G, Schruers K, Alciati A, Caldirola D. Novel investigational therapeutics for panic disorder. Expert Opin Investig Drugs 2015;24:491-505.
4. Bandelow B, Baldwin DS, Zwanzger P. Pharmacological treatment of panic disorder. Mod Trends Pharmacopsychiatry 2013;29:128-143.
5. Freire RC, Zugliani MM, Garcia RF, Nardi AE. Treatment-resistant panic disorder: a systematic review. Expert Opin Pharmacother 2016;17:159-168.
6. Perna G, Guerriero G, Caldirola D. Emerging drugs for panic disorder. Expert Opin Emerg Drugs 2011;16:631-645.
7. Freire RC, Hallak JE, Crippa JA, Nardi AE. New treatment options for panic disorder: clinical trials from 2000 to 2010. Expert Opin Pharmacother 2011;12:1419-1428.
8. Freire RC, Cosci F, Nardi AE. Update on pharmacological treatment of panic disorder. Minerva Psichiatrica 2011;52:145-155.
9. Boutros NN, Ghosh S, Khan A, Bowyer SM, Galloway MP. Anticonvulsant medications for panic disorder: A review and synthesis of the evidence. Int J Psychiatry Clin Pract 2014;18:2-10.
12. Bernik M, Ramos RT, Hetem LAB, Graeff F. Effect of single doses of pindolol and d-fenfluramine on flumazenil-induced anxiety in panic disorder patients. Behav Brain Res 2019;357-358:82-87.
15. Mantovani A, Aly M, Dagan Y, Allart A, Lisanby SH. Randomized sham controlled trial of repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex for the treatment of panic disorder with comorbid major depression. J Affect Disord 2013;144:153-159.
18. Buoli M, Dell’osso B, Bosi MF, Altamura C. Slow vs standard up-titration of paroxetine in the treatment of panic disorder: a prospective randomized trial. Psychiatry Clin Neurosci 2010;64:612-619.
19. Marquez M, Arenose H, Caruso N. Efficacy of alprazolam sublingual tablets in the treatment of the acute phase of panic disorders. Actas Esp Psiquiatr 2011;39:88-94.
20. Nardi A, Lopes F, Valença A, Freire R, Nascimento I, Veras A, et al. Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder. Psychiatry Res 2010;175:260-265.
21. Nardi A, Valença A, Freire R, Mochcovitch M, Amrein R, Sardinha A, et al. Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine. Braz J Med Biol Res 2011;44:366-373.
22. Nardi A, Freire R, Mochcovitch M, Amrein R, Levitan M, King A, et al. A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol 2012;32:120-126.
24. Prasko J, Zalesky R, Bares M, Horacek J, Kopecek M, Novak T, et al. The effect of repetitive transcranial magnetic stimulation (rTMS) add on serotonin reuptake inhibitors in patients with panic disorder: a randomized, double blind sham controlled study. Neuro Endocrinol Lett 2007;28:33-38.
25. Freire RC, Machado S, Arias-Carrion O, Nardi AE. Current pharmacological interventions in panic disorder. CNS Neurol Disord Drug Targets 2014;13:1057-1065.
26. Freire RC, Amrein R, Mochcovitch MD, Dias GP, Machado S, Versiani M, et al. A 6-year posttreatment follow-up of panic disorder patients: treatment with clonazepam predicts lower recurrence than treatment with paroxetine. J Clin Psychopharmacol 2017;37:429-434.
27. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl] piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011;54:3206-3221.
28. Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther 2015;145:43-57.
29. Connolly KR, Thase ME. Vortioxetine: a new treatment for major depressive disorder. Expert Opin Pharmacother 2016;17:421-431.
30. Guaiana G, Barbui C, Bighelli I, Trespidi C, Chiodo D, Cipriani A, et al. Antidepressants and benzodiazepines for panic disorder in adults. Cochrane Database Syst Rev 2016;9:CD011567
31. Moylan S, Staples J, Ward SA, Rogerson J, Stein DJ, Berk M. The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder. J Clin Psychopharmacol 2011;31:647-652.
32. Merideth C, Cutler AJ, She F, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol 2012;27:40-54.
35. Sepede G, De Berardis D, Gambi F, Campanella D, La Rovere R, D’Amico M, et al. Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol 2006;26:45-49.
36. Hoge EA, Worthington III JJ, Kaufman RE, Delong HR, Pollack MH, Simon NM. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr 2008;13:522-527.